Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

This study has been completed.
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: December 24, 2007
Last updated: October 1, 2009
Last verified: October 2009
The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study of Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Assess the sensitivity of RT-PCR to detect evidence of melanoma cells in bone marrow and/or peripheral blood and estimate sensitivity separately for each of the different stage groupings for melanoma [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Bone marrow and blood

Enrollment: 754
Study Start Date: October 1991
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Melanoma patients

Detailed Description:
Patients with melanoma can succumb to subclinical metastatic disease, not detectable at presentation by conventional physical examination, hematologic and biochemical screening, or radiologic evaluation. More intensive radiologic evaluation with CT or radioisotope scanning has not proven to be useful. What may be useful is a more sensitive method of staging melanoma patients at presentation, specifically evaluating them for subclinical systemic disease.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Melanoma Patients seen at Memorial Sloan-Kettering Cancer Center (MSK)

Inclusion Criteria:

MSK Patients with histologically confirmed melanoma of any site and at least one of the following:

  • Primary tumor > 4.0 mm thick (AJCC Stage IIB)
  • Clinically or histologically positive regional nodes (AJCC Stage III)
  • Any in transit disease (AJCC Stage III)
  • Any systemic metastases (AJCC Stage IV)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00588198

United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Principal Investigator: Danile Coit, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Robert Coit, MD, Memorial Sloan-Kettering Cancer Center Identifier: NCT00588198     History of Changes
Other Study ID Numbers: 91-125 
Study First Received: December 24, 2007
Last Updated: October 1, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Memorial Sloan Kettering Cancer Center:
histologically confirmed melanoma of any site

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on October 21, 2016